Jones 1982.

Study characteristics
Methods	Prospective, randomised, double‐blind, 2‐period cross‐over trial
Participants	54 people; aged 20‐37 years (n = 9), 38‐57 years (n = 23), > 58 years (n = 22) Tumour types: breast cancer (15 people), lymphoma (12 people), ovarian cancer (8 people), lung cancer (7 people), melanoma (3 people), testicular cancer (2 people), miscellaneous (7 people) Chemotherapy regimens: adriamycin‐based regimens (25 people), cisplatinum‐based regimens (14 people), other combinations (12 people). No information on doses reported Chemotherapy emetogenicity: high
Interventions	Nabilone 2 mg every 12 hours orally, n = 54 Placebo, n = 54
Outcomes	Episodes of nausea and vomiting unclear time period of results unclear; withdrawal due to severe nausea and vomiting; episodes of drowsiness, euphoria, hallucination, hypotension
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	24/54 (44%) participants received nabilone, 24/54 (44%) participants received placebo
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double‐blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double‐blind"